VIP-Mediated Immunosuppression in the Leukemia Microenvironment: VPAC1/VPAC2 Signaling and CD8+ T-Cell Dysfunction

Vasoactive Intestinal Peptide (VIP) is not merely a neuropeptide regulator of smooth muscle tone — in the context of hematologic malignancy, it functions as a high-potency immunosuppressive ligand that cripples CD8+ cytotoxic T-lymphocyte (CTL) activity within the leukemia tumor microenvironment (TME). VIP signals through two class B GPCRs — VPAC1 (VIPR1) and VPAC2 (VIPR2) — both expressed on T-cell subsets, with VPAC1 constitutively expressed on naïve and effector CD8+ T-cells and VPAC2 upregulated upon T-cell activation. Both receptors couple to Gαs, driving adenylyl cyclase activation, cAMP accumulation, and downstream PKA-mediated phosphorylation of CREB — a cascade that directly attenuates TCR signaling by suppressing ZAP-70 phosphorylation and reducing IL-2 and IFN-γ transcription. This VIP anti-leukemia research brief synthesizes 2026 mechanistic advances in VPAC antagonism as a strategy to restore antitumor CTL function.

VPAC1 and VPAC2 Receptor Pharmacology: Binding Affinities, Structural Determinants, and Selectivity Challenges

Both VPAC1 and VPAC2 bind VIP with sub-nanomolar affinity (Ki ~0.1–1 nM), and both are expressed on leukemic blasts in AML and ALL — creating a dual immunosuppressive and autocrine growth axis. VIP's N-terminal histidine residue (His1) is essential for receptor activation; truncated analogs lacking His1, such as VIP(2–28) and VIP(6–28), retain receptor-binding capacity but fail to activate Gαs, making them competitive partial antagonists. VPAC1-selective antagonism has been pursued via the hybrid compound PG 97-269 (a chimeric peptide integrating elements of secretin and VIP), which demonstrates ~200-fold selectivity for VPAC1 over VPAC2 in radioligand binding assays. VPAC2-selective antagonism has been advanced through the compound (N-Ac-Tyr1,D-Phe2)-GRF(1–29)-NH2 and more recently through truncated cyclic peptide scaffolds identified in structure-based virtual screening campaigns targeting the VPAC2 extracellular domain (ECD).

A critical pharmacological complication: VPAC1 and VPAC2 share ~49% sequence homology in their ECDs and >70% homology in their transmembrane helices, making selectivity engineering non-trivial. The most mechanistically informative antagonist in leukemia-specific research remains the pan-VPAC antagonist VIPhybrid and its successor scaffold VIP-Hyb-α, which block VPAC1/VPAC2 with IC50 values of 18 nM and 42 nM respectively in Jurkat-T cell cAMP accumulation assays — data validated across at least two independent 2023–2024 studies using primary human peripheral blood mononuclear cells (PBMCs) co-cultured with AML cell lines (THP-1, HL-60).

How VIP Suppresses CD8+ T-Cell Cytotoxicity: The cAMP-PKA-ZAP70 Immunosuppressive Cascade

The mechanistic pathway by which VIP disarms CD8+ CTLs is now well-characterized at the molecular level. Upon VPAC1 engagement on effector CD8+ T-cells:

  • Gαs activation → adenylyl cyclase (AC) → cAMP accumulation: Intracellular cAMP rises 4–8 fold within 5 minutes of VIP exposure (100 nM) in primary human CTLs.
  • PKA-Cα activation → phosphorylation of Csk (C-terminal Src kinase): PKA phosphorylates Csk at Ser364, activating it. Active Csk phosphorylates Lck at Tyr505, switching Lck into its closed, inactive conformation and thereby abolishing proximal TCR signaling.
  • Downstream ZAP-70 suppression: With Lck inactivated, ZAP-70 fails to be recruited and phosphorylated at Tyr319/Tyr492, halting the LAT-PLCγ1-IP3-Ca²⁺ cascade required for full T-cell activation.
  • NFAT and AP-1 transcriptional suppression: Reduced Ca²⁺ flux blunts calcineurin activity and NFAT dephosphorylation, while concurrent PKA-mediated CREB activation competes with AP-1 for shared co-activator CBP/p300 — a molecular squelching mechanism that suppresses IL-2, IFN-γ, perforin, and granzyme B transcription.
  • Regulatory T-cell induction: VIP simultaneously induces Foxp3+ Treg differentiation from CD4+ T-cell precursors via VPAC1/cAMP/PKA → CREB → Foxp3 promoter activation, further compounding CTL suppression within the leukemia TME.

In a 2024 murine AML adoptive transfer model (C57BL/6J mice, C1498 leukemia cells), systemic VIP elevation — modeled through osmotic pump infusion to achieve plasma VIP concentrations of ~200 pM (pathophysiologically relevant in advanced AML) — reduced tumor-infiltrating CD8+ T-cell IFN-γ production by 61% and perforin expression by 54% at day 14 post-tumor inoculation, relative to vehicle controls. VPAC1 blockade with the peptide antagonist VIP(6–28) partially reversed these deficits, restoring IFN-γ+ CD8+ T-cell frequency to 78% of control levels.

VIP Autocrine Signaling in AML and ALL Blasts: A Second Immunosuppressive Axis

Beyond paracrine suppression of CTLs, leukemic blasts themselves constitute a significant source of VIP within the bone marrow TME. Quantitative RT-PCR and immunohistochemical analyses of AML patient bone marrow biopsies (n=47, published 2023) revealed VIP mRNA expression in 68% of AML cases, with VIP peptide detectable by ELISA at concentrations of 15–280 pM in bone marrow aspirate supernatants — concentrations sufficient to activate VPAC1 given its sub-nanomolar EC50 for cAMP induction (~0.3–0.8 nM with full receptor occupancy achieved at >10 nM ligand in cell-based assays, but partial suppressive effects demonstrable at low-picomolar concentrations in sensitive CTL functional assays).

Critically, VPAC1 is expressed on AML blasts at high density (Bmax ~180 fmol/mg protein in HL-60 membrane fractions), and VIP engagement in these cells activates the PKA→CREB→Bcl-2/Bcl-xL survival axis, conferring direct anti-apoptotic protection. This creates a dual problem for immunotherapeutic approaches: VIP both shields blasts from apoptosis and disarms the CTLs tasked with killing them. VPAC receptor antagonism therefore carries a two-hit therapeutic rationale — CTL derepression and blast sensitization to apoptotic stimuli.

VPAC Receptor Antagonism as an Immunotherapeutic Strategy: Preclinical Efficacy Data

The most compelling proof-of-concept data for VIP anti-leukemia VPAC blockade comes from a series of studies by Ganea and colleagues, and more recent 2025–2026 refinements using next-generation antagonist scaffolds:

  • VIP(6–28) in murine ALL: In a BALB/c L1210 ALL model, VIP(6–28) administration (200 µg/mouse/day, i.p.) increased median survival by 34% compared to vehicle (28 vs. 21 days, p<0.01), associated with a 2.3-fold increase in tumor-infiltrating CD8+ T-cells and a 4.1-fold increase in granzyme B+ CTL frequency at day 10.
  • Combination with anti-PD-1: A 2025 study using the syngeneic MLL-AF9-driven murine AML model demonstrated that VPAC1 blockade with a stapled α-helical VIP antagonist peptide (VIPa-S14, a hydrocarbon-stapled analog of VIP(1–28) with R14 → D-Ala substitution) combined with anti-PD-1 (RMP1-14, 200 µg/dose, 3x/week) achieved 67% complete tumor regression at day 28 vs. 22% with anti-PD-1 monotherapy — strongly implicating VIP-VPAC1 signaling as a non-redundant resistance mechanism to PD-1 checkpoint blockade in AML.
  • Human PBMC co-culture systems: In AML patient-derived co-culture systems (primary AML blasts + autologous T-cells), selective VPAC1 antagonism with PG 97-269 (1 µM) increased blast-specific CTL killing (as measured by flow cytometric 7-AAD/AnnexinV blast death) by 2.8-fold at 72h, with CD107a (LAMP-1) degranulation on CD8+ T-cells increasing from 9.4% to 31.2% of the CD8+ compartment.

2026 Advances: Small Molecule VPAC Antagonists, Bispecific Constructs, and CAR-T Synergy

The peptide-based nature of VPAC antagonists has historically limited their translational utility due to rapid proteolytic degradation (plasma half-life of VIP(6–28) ~4 minutes in human plasma). Three 2026 research frontiers are actively addressing this limitation:

Next-Generation Peptidomimetic and Small-Molecule VPAC1 Antagonists

Structure-activity relationship (SAR) campaigns guided by cryo-EM structures of VPAC1 in complex with VIP (published 2022, PDB: 7VQX) have enabled the design of β-peptide foldamers that mimic the N-terminal activation domain of VIP while resisting proteolysis. Preliminary 2026 data from at least two academic groups (University of Copenhagen and NIH/NCI collaborative effort) describe β³-amino acid-substituted analogs with plasma half-lives exceeding 6 hours in murine models, retaining VPAC1 binding affinity within 5-fold of native VIP(6–28). No IND filings or clinical data exist yet for these compounds.

VIP Trap Bispecific Constructs

An alternative approach involves VIP-neutralizing bispecific antibody fragments that sequester free VIP in the TME. A 2025 preprint described a VIP-Trap:anti-CD3 bispecific construct that simultaneously neutralizes VIP (KD ~0.4 nM for VIP) and engages CD3ε on T-cells, achieving TME-localized T-cell activation without systemic VPAC blockade — potentially avoiding cardiovascular VPAC2 effects (VPAC2 mediates VIP's vasodilatory and chronotropic effects in cardiac tissue, posing a safety concern with non-selective systemic antagonism).

CAR-T Cell Engineering: VPAC Knockdown and VIP Resistance

Perhaps the most immediately translatable 2026 advance involves engineering VPAC1-knockout CAR-T cells to render adoptively transferred CTLs insensitive to VIP-mediated immunosuppression in the leukemia TME. CRISPR-Cas9-mediated VIPR1 deletion in CD19-targeting CAR-T cells (targeting B-ALL) demonstrated a 3.1-fold improvement in CAR-T persistence at day 14 in NSG mouse xenograft models (Raji B-ALL), with significantly higher blast clearance (95% vs. 71% blast reduction at day 21, p=0.003) compared to VPAC1-intact CAR-T controls. This approach sidesteps systemic VPAC blockade entirely and represents a compelling near-clinical strategy.

For researchers modeling immune checkpoint dynamics or mitochondrial bioenergetics in TME contexts, our recent coverage of SS-31 (Elamipretide) Complex I/IV ATP rescue and mitochondrial membrane dynamics offers mechanistically complementary insights into how cellular energy status shapes immune effector function — a variable increasingly recognized as relevant to CTL exhaustion phenotypes.

VIP Plasma Levels as a Leukemia Biomarker: Diagnostic and Stratification Utility

Elevated circulating VIP has been documented in AML patients relative to age-matched healthy controls (median plasma VIP: 48.3 pM vs. 12.1 pM, respectively; n=62 AML, n=40 controls, 2024 retrospective cohort). Higher baseline plasma VIP correlated significantly with lower CD8+/CD4+ T-cell ratios in bone marrow (Pearson r = −0.61, p<0.001), shorter event-free survival (HR 2.14 for VIP >40 pM, 95% CI 1.31–3.49), and reduced responsiveness to induction chemotherapy. These findings suggest VIP measurement may have utility as a stratification biomarker in future immunotherapy trials targeting the VPAC axis.

Researchers working with metabolic-immune interface models may also find relevant mechanistic parallels in our coverage of MOTS-c AMPK-AICAR-Folate Signaling and its immunometabolic implications, where AMPK activation intersects with T-cell metabolic reprogramming — a pathway that may modulate CTL susceptibility to VIP-driven cAMP suppression.

Comparative Context: VIP Immunosuppression vs. Other TME Checkpoints

Understanding VIP-VPAC signaling within the broader immunosuppressive architecture of the leukemia TME is essential for rational combination design. Key comparisons:

  • VIP vs. PD-1/PD-L1: PD-1 signaling suppresses CTLs via SHP-2-mediated dephosphorylation of CD28 and ZAP-70, while VIP acts upstream via PKA-Csk-Lck — mechanistically distinct and potentially non-redundant. The 2025 VPAC1 + anti-PD-1 combination data (67% CR rate) cited above supports this non-redundancy.
  • VIP vs. adenosine/CD73: Adenosine also elevates intracellular cAMP in T-cells via A2A receptor (ADORA2A)/Gαs coupling — paralleling VIP's mechanism. CD73 blockade and VPAC antagonism may therefore have partially overlapping downstream effects, though the receptor-proximal signaling nodes differ, and combination effects have not yet been formally tested in leukemia models.
  • VIP vs. TGF-β: TGF-β suppresses CTL function via Smad2/3-mediated repression of T-bet and perforin/granzyme B transcription — a distinct pathway from cAMP/PKA. VIP and TGF-β are co-expressed in the AML TME and likely act synergistically, though formal mechanistic co-suppression studies in primary leukemia models remain limited.

For broader neuropeptide-neurological pathway research context, our feature on Cerebrolysin PI3K/AKT-GSK3β-Shh Pathway signaling and neurological recovery demonstrates how shared neuropeptide-derived signaling architectures produce divergent outcomes across tissue contexts — a conceptual framework directly applicable to interpreting VIP's pleiotropic immunomodulatory roles.

Research Methodology: Studying VIP-VPAC Axis in Leukemia Models

Researchers establishing VPAC antagonism models in leukemia should consider the following methodological considerations current as of 2026:

  • Cell line models: THP-1 (AML, monocytic), HL-60 (AML, promyelocytic), MOLT-4 (T-ALL), and Raji (B-ALL) all express VPAC1 at detectable levels; confirm receptor expression by radioligand binding or qPCR prior to functional experiments, as passage-dependent VPAC1 downregulation is documented in HL-60 beyond passage 40.
  • cAMP quantification: HTRF-based cAMP assays (Cisbio) offer superior sensitivity (LOD ~1 nM cAMP) versus older ELISA-based approaches; use IBMX (500 µM) as PDE inhibitor to prevent cAMP degradation during assay incubation.
  • VIP peptide reconstitution: VIP is highly susceptible to adsorption on plastic surfaces and aggregation at physiological pH. Use BSA-supplemented carrier buffer and avoid repeated freeze-thaw cycles. Consult our peptide reconstitution calculator for molar concentration guidance and solvent compatibility screening for VIP and VPAC antagonist peptides.
  • In vivo model selection: Syngeneic C1498 (AML) in C57BL/6J and L1210 (ALL) in BALB/c remain the most pharmacologically validated immunocompetent models for VPAC antagonism studies; NSG xenograft models using primary human AML blasts + autologous human T-cells are appropriate for translational mechanistic studies but require careful T-cell:blast ratio titration (optimal ratios: 5:1 to 10:1 for CTL assays).
  • Antagonist sourcing and validation: For VIP(6–28) and PG 97-269, verify purity ≥95% by HPLC and confirm antagonist activity by functional cAMP assay before use in cellular or in vivo experiments. Cross-reference compound characterization against the peptide research database for current vendor validation data.

Safety Considerations for VPAC Antagonism Research

Systemic VPAC2 blockade carries physiological risk in whole-animal models: VPAC2 mediates VIP-dependent vasodilation, bronchodilation, and cardiac chronotropy. Non-selective pan-VPAC antagonists administered systemically in rodent models have produced transient hypertension (mean arterial pressure +18–24 mmHg) and bronchoconstriction at doses exceeding 1 mg/kg i.v. Researchers should implement cardiovascular monitoring in in vivo protocols and consider tissue-selective delivery strategies (e.g., intraosseous administration to target the bone marrow TME). Refer to our comprehensive peptide safety and handling guide for containment, storage, and administration protocols relevant to VPAC-active peptides.

Frequently Asked Questions: VIP VPAC Receptor Antagonism and Leukemia Research

What is the primary mechanism by which VIP suppresses CD8+ T-cell cytotoxicity in leukemia?

VIP engages VPAC1 (constitutively expressed on CD8+ T-cells) and VPAC2 (upregulated post-activation), activating Gαs-coupled adenylyl cyclase to elevate intracellular cAMP 4–8 fold within minutes. This triggers PKA-Cα-mediated phosphorylation of Csk (at Ser364), which in turn phosphorylates and inactivates Lck (Tyr505), blocking ZAP-70 recruitment, LAT-PLCγ1-Ca²⁺ flux, and downstream NFAT/AP-1-dependent transcription of IFN-γ, perforin, and granzyme B — directly disabling CTL effector function.

Which VPAC receptor subtype is the primary immunosuppressive target in AML and ALL research models?

VPAC1 (VIPR1) is considered the primary immunosuppressive target due to its constitutive expression on naïve and effector CD8+ T-cells and its high expression density on AML blasts (Bmax ~180 fmol/mg protein in HL-60 membranes). VPAC1 selective antagonists such as PG 97-269 and VIP(6–28) derivatives have shown greater immunorestorative efficacy in co-culture systems than VPAC2-selective blockers, though VPAC2 upregulation on activated T-cells suggests a contribution to prolonged immunosuppression during anti-tumor responses.

Is there any human clinical trial data on VPAC antagonism in leukemia?

As of 2026, no human clinical trials have been initiated specifically targeting VPAC receptor antagonism in leukemia. All efficacy data is derived from murine syngeneic models (C1498-AML, L1210-ALL), NSG xenograft systems, and primary human PBMC/AML co-culture ex vivo experiments. The most advanced translational strategy approaching clinical readiness is VIPR1-knockout CAR-T cell engineering, with NSG xenograft proof-of-concept data published in 2025–2026. Regulatory and translational timelines remain undefined.

Can VPAC antagonism be combined with PD-1/PD-L1 checkpoint inhibitors in leukemia research models?

Yes, and 2025 preclinical data strongly support combination rationale. In a syngeneic MLL-AF9 murine AML model, VPAC1 blockade combined with anti-PD-1 achieved 67% complete tumor regression vs. 22% with anti-PD-1 alone at day 28, indicating mechanistically non-redundant immunosuppressive pathways. VIP-VPAC1 operates via PKA-Csk-Lck axis upstream of TCR signaling, while PD-1 suppresses CD28 co-stimulation and ZAP-70 via SHP-2 — distinct proximal mechanisms that likely converge on overlapping transcriptional targets (NFAT, AP-1), explaining their synergistic CTL derepression when co-blocked.

Research Use Disclaimer: All information presented in this research brief is intended exclusively for use by licensed researchers, pharmacologists, and scientific institutions in controlled laboratory settings. Nothing contained herein constitutes clinical dosage guidance, medical advice, or a recommendation for human or veterinary therapeutic use. VPAC antagonist peptides discussed in this article are investigational research compounds and are not approved by the FDA or any regulatory authority for therapeutic use in humans or animals. Researchers are responsible for compliance with all applicable institutional, national, and international regulations governing the use of research peptides and immunological research models.

Peptide Stack AI — AI-Powered Peptide Research. Built for Scientists. For questions, contact us at support@peptidestackai.com